Collapsed Cakes - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Collapsed Cakes

Equipment and Processing Report

Untitled Document

Q: We have changed the brand of our stoppers for a product that we freeze-dry in vials. Since the change, we have observed a significant increase in rejects for collapsed cakes. Why are the cakes collapsing? What can we do to prevent this problem?

A: When selecting stoppers, we take great care to specify various details, such as the formulation of the rubber, the quality of its surface, and the surface treatment, out of concern for the stability of our product. One important specification, however, is sometimes overlooked. This specification is the surface area of the openings or windows in the stopper that result when the stopper is placed on the vial at the prestoppering stage. The window is the route by which water vapor exits the vial during sublimation and desorption; it restricts the passage of vapor.

When you changed the brand of stoppers, you may have reduced the surface area of the window inadvertently. Smaller windows provide greater restriction and could increase the pressure inside the vial, thus causing a consequent increase in sublimation-front temperature. If this temperature exceeds the collapse temperature, you will find an increased number of collapsed cakes. Examine the window geometries of your old and new brands of stoppers and evaluate whether they have equivalent surface areas.

—Robert Bullich, process development manager at TELSTAR


If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here